Del 17 p is considered a high risk feature in myeloma. Only nine patients with AL amyloidosis (2%) were identified with a deletion (17p) in a recent retrospective study of 401 patients published by the Mayo Clinic Group. The nine patients with deletion 17p had the highest level of bone marrow plasma cell infiltration. No significant difference in overall survival for the high-risk FISH features could be documented, but the study was limited by very small numbers of high risk abnormalities. In the absence of hard data in AL amyloidosis, I would err on the side of considering del 17p as a high-risk feature. Usually bortezomib-based therapies are considered more effective in patients with del 17p.